收费全文 | 44518篇 |
免费 | 2864篇 |
国内免费 | 253篇 |
耳鼻咽喉 | 399篇 |
儿科学 | 1292篇 |
妇产科学 | 1205篇 |
基础医学 | 5915篇 |
口腔科学 | 943篇 |
临床医学 | 4467篇 |
内科学 | 9704篇 |
皮肤病学 | 888篇 |
神经病学 | 4780篇 |
特种医学 | 1508篇 |
外科学 | 5892篇 |
综合类 | 172篇 |
一般理论 | 19篇 |
预防医学 | 3221篇 |
眼科学 | 760篇 |
药学 | 2777篇 |
1篇 | |
中国医学 | 84篇 |
肿瘤学 | 3608篇 |
2024年 | 53篇 |
2023年 | 474篇 |
2022年 | 416篇 |
2021年 | 1801篇 |
2020年 | 1059篇 |
2019年 | 1485篇 |
2018年 | 1700篇 |
2017年 | 1189篇 |
2016年 | 1339篇 |
2015年 | 1551篇 |
2014年 | 2127篇 |
2013年 | 2657篇 |
2012年 | 3925篇 |
2011年 | 3922篇 |
2010年 | 1983篇 |
2009年 | 1850篇 |
2008年 | 3131篇 |
2007年 | 3009篇 |
2006年 | 2720篇 |
2005年 | 2684篇 |
2004年 | 2249篇 |
2003年 | 2012篇 |
2002年 | 1777篇 |
2001年 | 241篇 |
2000年 | 173篇 |
1999年 | 237篇 |
1998年 | 302篇 |
1997年 | 225篇 |
1996年 | 199篇 |
1995年 | 183篇 |
1994年 | 156篇 |
1993年 | 121篇 |
1992年 | 91篇 |
1991年 | 85篇 |
1990年 | 70篇 |
1989年 | 45篇 |
1988年 | 43篇 |
1987年 | 36篇 |
1986年 | 35篇 |
1985年 | 37篇 |
1984年 | 38篇 |
1983年 | 23篇 |
1982年 | 41篇 |
1981年 | 24篇 |
1980年 | 21篇 |
1979年 | 14篇 |
1978年 | 14篇 |
1977年 | 15篇 |
1975年 | 8篇 |
1972年 | 9篇 |
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献Methods: Patients were divided into two groups: Group A (22 patients) who underwent ACL reconstruction performed with an All-Inside graft-link technique; Group B (22 patients) who underwent ACL reconstruction with an Out-In technique and DGST graft. At a mean follow-up of 13 months, quadriceps and hamstring isokinetic peak torque deficits were recorded.
Results: In group A, the mean side to side peak torque flexion difference between the operated and non-operated limbs was ?3% and the mean torque at 30° was ?7.5% at high angular velocity (180°/sec); the mean peak flexion torque was 7.2% and the mean torque at 30° was 3.1% at low angular velocity (60°/sec).
In group B, the mean side to side peak flexion torque was ?3.5% and the mean torque at 30° was ?7.6% at high angular velocity (180°/sec); the mean peak flexion torque was ?7.2% and the mean torque at 30° was ?11% at low angular velocity (60°/sec).
A statistically significant difference was found between the two groups at lower angular velocity both for the mean peak flexion torque and the mean torque at 30° (p = 0.009), with better results in the study group.
Discussion/conclusion: Gracilis sparing technique is a minimally invasive technique for ACL reconstruction and yielded a significantly better flexion strength recovery at lower angular velocity compared to a full tibial tunnel technique with DGST for ACL reconstruction. 相似文献